following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
.
.
by using this website you consent to our use of cookies. for information on cookies see our
.
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years.
.
.
.
stephen silberstein, md, director, jefferson university headache center.
.